Gene therapy: Designer promoters for tumour targeting

Trends in Genetics

Volumn 16, Issue 4, 2000, Pages 174-181

  Nettelbeck, Dirk M ^a   Jérôme, Valérie ^a   Müller, Rolf ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA LACTOGLOBULIN; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; CREATINE KINASE; CYCLINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MONOPHENOL MONOOXYGENASE; MYELIN BASIC PROTEIN; NUCLEAR FACTOR; OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN; RETINOBLASTOMA PROTEIN; SUCRASE ISOMALTASE; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR E2F; VASCULOTROPIN RECEPTOR;

CANCER; CANCER THERAPY; CELL CYCLE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY; TRANSGENE; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; CELL CYCLE; ENDOTHELIUM, VASCULAR; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 0034175969     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-9525(99)01950-2     Document Type: Review

References (73)

1. Culver K.W., Blaese R.M. Gene therapy for cancer. Trends Genet. 10:1994;174-178.
2. Vile R.G., Hart I.R. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53:1993;962-967.
3. Vile R.G., Hart I.R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53:1993;3860-3864.
4. Vile R.G.et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54:1994;6228-6234.
5. Hughes B.W.et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55:1995;3339-3345.
6. Diaz R.M.et al. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J. Virol. 72:1998;789-795.
7. Vile R.G.et al. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology. 214:1995;307-313.
8. Pang S.et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Ther. 6:1995;1417-1426.
9. Lee C.H.et al. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res. 16:1996;1805-1811.
10. Martiniello W.R.et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Ther. 9:1998;1617-1626.
11. Kuriyama S.et al. A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct. Funct. 16:1991;503-510.
12. Hobson B., Denekamp J. Endothelial proliferation in tumours and normal tissues. continuous labelling studies Br. J. Cancer. 49:1984;405-413.
13. Vartanian R.K., Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am. J. Pathol. 144:1994;1188-1194.
14. Jaggar R.T.et al. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. Hum. Gene Ther. 8:1997;2239-2247.
15. Walton T.et al. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. Anticancer Res. 18:1998;1357-1360.
16. Graulich W.et al. Cell type specificity of the human endoglin promoter. Gene. 227:1999;55-62.
17. Huber B.E.et al. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma. an innovative approach for cancer therapy Proc. Natl. Acad. Sci. U. S. A. 88:1991;8039-8043.
18. Kaneko S.et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55:1995;5283-5287.
19. Ido A.et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 55:1995;3105-3109.
20. Arbuthnot P.B.et al. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum. Gene Ther. 7:1996;1503-1514.
21. Kanai F.et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 57:1997;461-465.
22. Osaki T.et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54:1994;5258-5261.
23. Tanaka T.et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 56:1996;1341-1345.
24. Lan K.H.et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 57:1997;4279-4284.
25. Tanaka T.et al. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Biochem. Biophys. Res. Commun. 231:1997;775-779.
26. Brand K.et al. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther. 5:1998;1363-1371.
27. Cao G.et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther. 6:1999;83-90.
28. Dachs G.U.et al. Targeting gene expression to hypoxic tumor cells. Nat. Med. 3:1997;515-520.
29. Harris J.D.et al. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1:1994;170-175.
30. Ring C.J.et al. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther. 3:1996;1094-1103.
31. Stackhouse M.A.et al. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Ther. 6:1999;209-219.
32. Vassaux G.et al. Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. 6:1999;1192-1197.
33. Chen L.et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 96:1995;2775-2782.
34. Tai Y.T.et al. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res. 59:1999;2121-2126.
35. Massuda E.S.et al. Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14701-14706.
36. Judde J.G.et al. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum. Gene Ther. 7:1996;647-653.
37. Gutierrez M.I.et al. Switching viral latency to viral lysis. a novel therapeutic approach for Epstein-Barr virus-associated neoplasia Cancer Res. 56:1996;969-972.
38. Franken M.et al. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nat. Med. 2:1996;1379-1382.
39. Weichselbaum R.R.et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 54:1994;4266-4269.
40. Seung L.P.et al. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 55:1995;5561-5565.
41. Hallahan D.E.et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1:1995;786-791.
42. Joki T.et al. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum. Gene Ther. 6:1995;1507-1513.
43. Mauceri H.J.et al. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56:1996;4311-4314.
44. Manome Y.et al. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter. activation by ionizing radiation or uptake of radioactive iododeoxyuridine Hum. Gene Ther. 9:1998;1409-1417.
45. Kawashita Y.et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum. Gene Ther. 10:1999;1509-1519.
46. Walther W.et al. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther. 4:1997;544-552.
47. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
48. Parr M.J.et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 3:1997;1145-1149.
49. Zwicker J.et al. Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J. 14:1995;4514-4522.
50. Nettelbeck D.M.et al. Cell cycle regulated promoters for the targeting of tumor endothelium. Adv. Exp. Med. Biol. 451:1998;437-440.
51. Nettelbeck D.M.et al. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther. 5:1998;1656-1664.
52. Richards C.A.et al. Transcriptional regulatory sequences of carcinoembryonic antigen. identification and use with cytosine deaminase for tumor-specific gene therapy Hum. Gene Ther. 6:1995;881-893.
53. Pang S.et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 57:1997;495-499.
54. Siders W.M.et al. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 56:1996;5638-5646.
55. Siders W.M.et al. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther. 5:1998;281-291.
56. Ishikawa H.et al. Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting hepatocellular carcinoma. Gene Ther. 6:1999;465-470.
57. Stein U.et al. Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent. J. Cancer Res. Clin. Oncol. 122:1996;275-282.
58. Li X.et al. Synthetic muscle promoters. activities exceeding naturally occurring regulatory sequences Nat. Biotechnol. 17:1999;241-245.
59. Su H.et al. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene Ther. 7:1996;463-470.
60. Su H.et al. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc. Natl. Acad. Sci. U. S. A. 94:1997;13891-13896.
61. Segawa T.et al. Prostate-specific amplification of expanded polyglutamine expression. a novel approach for cancer gene therapy Cancer Res. 58:1998;2282-2287.
62. Jérôme V., Müller R. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum. Gene Ther. 9:1998;2653-2659.
63. Liu N.et al. CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Nucleic Acids Res. 25:1997;4915-4920.
64. Zwicker J.et al. CDF-1-mediated repression of cell cycle genes targets a specific subset of transactivators. Nucleic Acids Res. 25:1997;4926-4932.
65. Nettelbeck D.M.et al. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Ther. 6:1999;1276-1281.
66. Bischoff J.R.et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
67. Rodriguez R.et al. Prostate attenuated replication competent adenovirus (ARCA) CN706. a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res. 57:1997;2559-2563.
68. Yu D.C.et al. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59:1999;1498-1504.
69. Alemany R.et al. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 6:1999;21-25.
70. Hallenbeck P.L.et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10:1999;1721-1733.
71. Miyatake S.et al. Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71:1997;5124-5132.
72. Bilbao G.et al. Improving adenoviral vectors for cancer gene therapy. Tumor Targeting. 3:1998;59-79.
73. Harvey D.M., Caskey C.T. Inducible control of gene expression. prospects for gene therapy Curr. Opin. Chem. Biol. 2:1998;512-518.